Notícias e Atividades da Guardant Health

Guardant Health é uma empresa listada sob o símbolo GH (US).

Veja o organograma con seus 31 executivos principais

Biografias mais buscadas da Guardant Health

• Helmy Eltoukhy, Chairman of the Board and Co-Chief Executive Offic...
• Vijaya Gadde, Director
• Steve Krognes, Director

Recentes movimentos de executivos em Guardant Health

• Craig Eagle, Chief Medical Officer, deixará a Companhia em 8 de mai. de 2026  (Notícia publicada em 28 de abril de 2026).
• Matthew Ellis, Senior Vice President, Clinical Development Precision Oncology, deixou a Companhia  (Notícia publicada em 18 de dezembro de 2025).
• Alex Azar, ingressou na Companhia como Director  (Notícia publicada em 16 de setembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Guardant Health.

Guardant Health possui 3.499 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Kaiser Permanente (Estados Unidos) e HCA (Estados Unidos).

Popular M&A news in Saúde

• Adaptive Innovations acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 4 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Freeman Health System adquiriu Northwest Health (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Saúde

• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board da Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer da Royalty Pharma

Saiba mais sobre a indústria do Saúde

Últimos comunicados de imprensa de Guardant Health

• American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines
• Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting
• FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
• Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
• Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
• Guardant Health to Participate in Upcoming Investor Conferences
• Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026
• Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan
• View more press releases Close

Redes sociais sobre Guardant Health

• Guardant Health na Wikipedia, Google News e Yahoo Finance
• Guardant Health na LinkedIn, X (Twitter) e YouTube